Role of mannose-binding lectin in the innate defense against Candida albicans: Enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells by Ip, WK & Lau, YL
Title
Role of mannose-binding lectin in the innate defense against
Candida albicans: Enhancement of complement activation, but
lack of opsonic function, in phagocytosis by human dendritic
cells
Author(s) Ip, WK; Lau, YL
Citation Journal Of Infectious Diseases, 2004, v. 190 n. 3, p. 632-640
Issued Date 2004
URL http://hdl.handle.net/10722/43148
Rights Journal of Infectious Diseases. Copyright © University ofChicago Press.
632 • JID 2004:190 (1 August) • Ip and Lau
M A J O R A R T I C L E
Role of Mannose-Binding Lectin in the Innate
Defense against Candida albicans: Enhancement
of Complement Activation, but Lack of Opsonic
Function, in Phagocytosis by Human Dendritic Cells
Wai-Kee Ip and Yu-Lung Lau
Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Mannose-binding lectin (MBL) is a serum collectin believed to be of importance in innate immunity. We have
investigated the role of MBL in the first-line defense against Candida albicans, an opportunistic fungal path-
ogen. MBL bound C. albicans via its lectin domain, resulting in agglutination of the organisms upon their
outgrowth of hyphae. In a human in vitro MBL system, deposition of C4 fragments on C. albicans was
increased when exogenous MBL was added to serum samples from MBL-deficient individuals. Similar en-
hancement of deposition of iC3b also was observed. MBL and enhanced opsonic C3 fragments mediated by
MBL did not facilitate opsonophagocytosis of the organisms by monocyte-derived dendritic cells (DCs). How-
ever, MBL was found to inhibit the growth of C. albicans independently of complement activation, although,
with complement activation, further inhibition was observed. We concluded that MBL plays an important
role in the first-line defense against C. albicans without the need for opsonophagocytosis by DCs, in which
a direct interaction of MBL with C. albicans results in agglutination and accelerated complement activation
via the lectin pathway, leading to inhibition of growth.
Mannose-binding lectin (MBL) is a serum protein of
hepatic origin that belongs to the collectin family [1]
and plays an important role in innate immunity [2, 3].
MBL binds, through multiple lectin domains, to car-
bohydrate structures on microbial surfaces and is be-
lieved to mediate direct killing via complement acti-
vation [4] or via enhancing phagocytosis by acting as
an opsonin [5–7]. On binding to a sugar-rich micro-
bial surface, MBL activates the complement system via
MBL-associated serine protease (MASP)–2 [8]. The ac-
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tivated serine protease is then able to cleave, sequen-
tially, C4 and C2, resulting in the generation of cova-
lently bound C4b2a complexes, C3 convertases, which
allows conversion of C3 into C3a and C3b/iC3b, the
key reaction leading to initiation of the terminal path-
way. Accumulating evidence has shown that MBL can
modulate the host inflammatory response to infections
in both ex vivo and in vivo models [6, 9–12].
In humans, a single MBL gene on chromosome 10
encodes the protein [13, 14]. MBL deficiency and low
levels of serum MBL are strongly associated with the
gene polymorphisms in the exon 1 [15–18] and pro-
moter regions [19]. At present, 7 different haplotypes
have been described, and 4 of these (LYPB, LYQC,
HYPD, and LXPA) are associated with low levels of the
protein [20]. In many populations, MBL deficiency is
the most common immunodeficiency described at pres-
ent, and several clinical studies have established an as-
sociation between MBL deficiency and susceptibility to
disease [21, 22].
Candida albicans is a component of the normal mi-
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croflora of the alimentary tract and mucocutaneous membranes
of the healthy host. However, when immune defenses are com-
promised or the normal microflora balance is disrupted, Can-
dida organisms transform into opportunistic pathogens. In-
deed, dissemination of Candida organisms is the leading cause
of invasive fungal disease in premature infants, diabetic pa-
tients, and surgical patients and of oropharyngeal disease in pa-
tients with AIDS [23–29]. C. albicans can switch from a uni-
cellular yeast form into various filamentous hyphal forms, all
of which can be found in infected tissues [30]. The ability of
C. albicans to alter its cell structure from a yeast form to a
hyphal form enables the fungus to adhere to host cells and
penetrate tissues [31]. This dimorphic growth is thought to be
an important virulence factor [32, 33]. For this to be possible,
mechanisms must exist in the host defense to target such es-
sential aspects of the pathogenicity of C. albicans. Recent evi-
dence indicates that dendritic cells (DCs), which are potent
professional antigen-presenting cells, can induce cell-mediated
immunity on interaction with C. albicans, by phagocytosis, kill-
ing, and antigen presentation [34] and are also capable of sens-
ing different forms of the fungus by discriminative production
of cytokines [35, 36].
MBL has the capacity to function as an opsonin—in particular,
for phagocytosis by neutrophils [6, 7]—and has been shown to
strongly bind C. albicans [37]. The role of MBL in the host
defense against C. albicans, however, remains unclear. In the
present study, we examined the role of MBL in the innate defense
against C. albicans, including opsonophagocytosis by DCs.
MATERIALS AND METHODS
C. albicans. C. albicans strain ATCC 90028 was maintained
on Sabouraud dextrose agar (Difco Laboratories) at 4C. Or-
ganisms were grown for 16 h in brain-heart infusion broth
(Oxoid) at 37C, with orbital shaking at 200 rpm before use.
Under these conditions, C. albicans grew as a 195% pure yeast-
phase population. Immediately before each experiment, organ-
isms were harvested by centrifugation, washed 3 times in
Hanks’ balanced salt solution (HBSS; Gibco-BRL), and resus-
pended to the appropriate concentration in HBSS containing
5 mmol/L CaCl2 and 5 mmol/L MgCl2 (HBSS
++).
Binding of MBL to C. albicans. C. albicans yeasts (2
107 cells/mL) were incubated with 5 mg/mL purified MBL (a
gift from Prof. M. W. Turner, Institute of Child Health, London;
purified MBL is known to be noncovalently associated with
MASPs in their preparation, as described elsewhere [4]), in a
total volume of 50 mL of HBSS++, for 10 min at 37C. The
yeasts were then spun for 2 min at 10,000 g, and the pellets
were washed with HBSS before resuspension in fluorescein iso-
thiocyanate (FITC)–conjugated anti–human-MBL monoclonal
antibody (4 mg/mL in HBSS; HYB 131-01; AntibodyShop). Af-
ter 15 min of incubation on ice, the samples were centrifuged
and washed as described above and were fixed in 1% (vol/vol)
formaldehyde and 1% (wt/vol) glucose in PBS, for flow cy-
tometry. MBL binding was measured by use of flow cytometry
performed on an EPICS Elite ESP (Coulter) at a low flow rate.
Data were evaluated as mean fluorescence intensity (MFI).
Negative controls were established for MBL binding by the
omission of MBL. For inhibition experiments, 20 mmol/L EDTA
or 2 mg/mL mannan from Saccharomyces cerevisiae (Sigma-Al-
drich) was added to the MBL solution 5 min before the addition
of MBL to the yeasts.
Influence of MBL on formation of hyphae of C. albicans.
C. albicans yeasts ( cells/mL) were incubated with or with-61 10
out 5 mg/mL purified MBL in 100 mL of HBSS++ with 10% heat-
inactivated fetal calf serum (FCS; Gibco-BRL), in 96-well tissue-
culture plates (Corning-Costar) (100 mL/well), for up to 3 h at
37C (5% CO2). The use of serum-rich medium and culturing
at 37C (5% CO2) stimulates germination of C. albicans yeasts.
C. albicans was analyzed by use of light microscopy, to determine
the influence of MBL on formation of hyphae. Agglutination of
C. albicans yeast (unicellular) or hyphae (filamentous), in the
presence of MBL, was also evaluated by use of flow cytometry
(scatter plots) or light microscopy, respectively.
Deposition of C4 and iC3b on C. albicans. Serum samples
were available for study from 6 MBL-deficient but generally
healthy blood donors. Ethical approval was obtained for the
present study from the Institutional Review Board of the Uni-
versity of Hong Kong/Hospital Authority Hong Kong West
Cluster. All of the blood donors were homozygous for the LYPB
haplotype of the MBL gene and had undetectable levels of se-
rum MBL (!0.05 mg/mL), which were determined as described
elsewhere [38, 39]. The freshly prepared MBL-deficient serum
samples from these individuals were aliquoted and stored at
70C until use.
C. albicans yeasts ( cells/mL) were incubated in 50 mL72 10
of HBSS++ containing 20% MBL-deficient serum supplemented
with or without 5 mg/mL purified MBL, in Eppendorf tubes
for 1, 2, 4, 8, 16, or 32 min at 37C. The reaction in each tube
was stopped by adding 1 mL of ice-cold HBSS containing 1%
paraformaldehyde. Suspensions were spun for 2 min at 10,000
g. The supernatants were removed, and pellets were washed in
0.5 mL of HBSS before suspension in monoclonal anti-C4d (4
mg/mL in HBSS; Quidel), which recognizes C4, C4b, and C4d.
After 15 min of incubation on ice, the samples were centrifuged
and washed as described above and were resuspended in FITC–
anti–mouse IgG1 (4 mg/mL in HBSS; BD PharMingen). The
mixtures were incubated for a further 15 min on ice. Suspen-
sions were centrifuged and washed, and samples were then fixed
in 1% (vol/vol) formaldehyde and 1% (wt/vol) glucose in PBS,
for flow cytometry. Deposition of C4 was evaluated for each
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MBL-deficient serum sample in duplicate by use of flow cy-
tometry performed as described above for MBL binding.
After the mixtures were incubated, as described above, for
up to 32 min, deposition of iC3b was also determined in sep-
arate tubes in which monoclonal anti-iC3b (4 mg/mL in HBSS;
Quidel) and FITC–anti–mouse IgG2b (4 mg/mL in HBSS; BD-
Pharmingen) were used instead of monoclonal anti-C4d and
FITC–anti–mouse IgG1, respectively. Evaluation of deposition
of iC3b was also the same as for deposition of C4d (i.e., by
flow cytometry).
Preparation of human DCs. DCs were prepared as de-
scribed elsewhere [40]. In brief, peripheral blood was obtained
from healthy blood donors, and peripheral blood mononuclear
cells (PBMCs) were isolated by sedimentation over Ficoll-Paque
gradient (Pharmacia Biotech). To generate immature DCs, mono-
cytes positively selected from PBMCs by use of anti-CD14 mi-
crobeads (Mitenyi Biotec) were cultured in 24-well tissue-cul-
ture plates (Corning-Costar) (1 mL/well) at a concentration of
cells/mL in RPMI 1640 medium (Gibco-BRL) con-61 10
taining 10% FCS (Gibco-BRL), human recombinant granulo-
cyte-macrophage colony-stimulating factor (50 ng/mL; R&D
Systems), and human recombinant interleukin-4 (10 ng/mL;
R&D Systems) for 7 days. At days 6–7, 195% of the cells were
CD14CD11c+HLA-DR+ DCs, as determined by use of 3-color
flow cytometry. DCs were studied after 6–7 days of culture.
Opsonophagocytosis of C. albicans by DCs. C. albicans
yeasts were labeled with green-fluorescent dye PKH67 (Sigma),
in accordance with the manufacturer’s protocol. Phagocytosis
was evaluated by use of an MOI of 5 organisms:1 DC. PKH67-
labeled yeasts ( cells/mL) were incubated in 125 mL of72 10
HBSS++ containing 20% MBL-deficient serum supplemented
with or without purified MBL (1 or 5 mg/mL), in Eppendorf
tubes for 16 min at 37C. The reaction was stopped by adding
1 mL of ice-cold HBSS. The suspensions were spun for 2 min
at 10,000 g. The supernatants were discarded, and the pellets
were resuspended in 0.25 mL of serum-free RPMI 1640 me-
dium ( cells/mL) and then were transferred to 24-well610 10
tissue-culture plates (Corning-Costar) (0.25 mL/well). DCs (2
106 cells/mL) in 0.25-mL aliquots, in serum-free RPMI 1640
medium, were added, and the mixtures, in a final volume of
0.5 mL, were incubated for 1 h at 37C with orbital shaking
at 150 rpm. A 1-mm volume of ice-cold HBSS was added to
stop phagocytosis. The samples were spun, and pellets were re-
suspended in 200 mL of trypan blue (Gibco-BRL) (1 mg/mL in
HBSS) and incubated for 10 min at 25C, to quench the fluo-
rescence of bound, but not engulfed, organisms, as described
elsewhere [34]. The samples then were washed and fixed in 1%
(vol/vol) formaldehyde and 1% (wt/vol) glucose in PBS, for flow
cytometry. Phagocytosis of the PKH67-labeled C. albicans was
evaluated by determining the percentage of DCs associated with
these labeled organisms in the entire population of DCs. The
maximum percentages obtained within an experiment were as-
signed a value of 100%, with all other percentages within the
same experiment expressed as a relative percentage of this max-
imum. Negative controls were established for opsonophagocy-
tosis of C. albicans, by incubating organisms in HBSS++ con-
taining neither serum nor purified MBL in the opsonization step.
Influence of MBL on growth of C. albicans. Freshly grown
C. albicans yeasts ( cells/mL) were incubated with or72 10
without 5 mg/mL purified MBL in HBSS++ for 15 min at 37C.
The yeast cells were washed with HBSS, resuspended in RPMI
1640 medium at cells/mL, and then transferred to 96-61 10
well tissue-culture plates (50 mL/well). To each well was added
50 mL of 2.5% MBL-deficient serum diluted in RPMI 1640
medium, 2.5% MBL-deficient serum heat inactivated for 30
min at 56C and diluted in RPMI 1640 medium, or RPMI 1640
medium alone. The final concentration of serum used (1.25%/
well) was determined to be the highest concentration giving
minimal growth-inhibitory effect on C. albicans by our separate
experiments in which yeast cells were incubated with a range
of concentrations (0.625%–80%) of pooled human serum se-
rially diluted in RPMI 1640 medium or with RPMI alone, for
6 h 37C, and the growth of C. albicans was determined by use
of the XTT-based cell proliferation assay (XTT-assay; Roche),
as adapted from previous reports [41, 42]. The yeasts, in a final
volume of 100 mL of culture medium/well, were incubated at
37C (5% CO2). After 3 and 6 h of incubation, the growth of
C. albicans was determined by use of the XTT-assay. In brief,
50 mL of the XTT-labeling mixture, prepared according to the
manufacturer’s protocol (Roche), was added to each well. The
plates were then incubated in the dark for up to 2 h at 37C
(5% CO2). A colorimetric change in the XTT-assay was then
measured in terms of the absorbance at 490 nm by use of a
microtiter plate reader (Model 550; Bio-Rad).
Statistical analysis. Data are expressed as .mean SEM
Statistical significance was determined by paired Student’s t
tests, by use of Instat (version 3.05; GraphPad Software). P !
was considered to be significant..05
RESULTS
Binding of MBL to C. albicans. Binding of MBL to C. al-
bicans was observed at 5 mg/mL, a concentration within the
range of physiological levels (e.g., !0.02–10 mg/mL in southern
Chinese persons [39]) (figure 1A). The binding was markedly
reduced in the absence of Ca2+ (figure 1B) or in the presence
of mannan (figure 1C).
Influence of MBL on formation of hyphae of C. albicans.
Light microscopic analysis revealed that, in terms of the length
of hyphae, MBL (5 mg/mL) had no influence on the formation
of hyphal structures. C. albicans yeast in the presence or absence
of MBL germinated and formed hyphae within 3 h. However,
in the presence of MBL, agglutination was induced upon the
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Figure 1. Ca2+-dependent carbohydrate binding underlying interaction
of mannose-binding lectin (MBL) with Candida albicans. C. albicans were
incubated in the presence of MBL (5 mg/mL) in Hanks’ balanced salt
solution (HBSS) containing 50 mmol/L CaCl2 and 50 mmol/L MgCl2
(HBSS++) (A), HBSS with 20 mmol/L EDTA (B), or HBSS++ with 2 mg/mL
mannan (C). EDTA or mannan was added to the MBL solution 5 min
before addition to the yeast. After incubation with fluorescein isothio-
cyanate–conjugated mouse anti–human-MBL monoclonal antibody, bind-
ing of MBL to C. albicans was analyzed by use of flow cytometry, as
shown in the representative histograms (A–C). Black lines, MBL binding;
gray lines, negative controls.
outgrowth of hyphae as early as 1 h of incubation (figure 2C–
2F). Such MBL-induced agglutination did not happen to C.
albicans, which were still in the yeast phase by 20 min (figure
2A), when analyzed by use of flow cytometry (scatter plots)
(figure 2B).
Deposition of C4 and iC3b on C. albicans. C. albicans
yeasts were incubated with 20% serum from each of the 6 MBL-
deficient individuals, to which purified MBL (5 mg/mL) was
added. The time course of deposition of MBL, C4, and iC3b
on the yeast cells was determined by use of flow cytometry
(figure 3A). No detectable deposition of MBL was found on
C. albicans incubated with MBL-deficient serum. Only when
exogenous MBL was added to the serum did deposition of MBL
become detectable (as early as 30 s), and it attained high lev-
els of deposition over subsequent time points (up to 32 min)
(figure 3B). The deposition of an early cleavage product of
complement activation, C4, was detected by 1 min of incu-
bation in serum, as shown in figure 3C. The amount of C4
appeared to be significantly enhanced by MBL at 4 min and
up to 8 min ( , paired Student’s t test of MFI; ).P ! .05 np 6
In the presence of MBL, deposition of C4 was maximal at 8
min, whereas, in the absence of MBL, deposition of C4 attained
its maximal amount slowly over the time course measured.
Deposition of opsonic iC3b was detected after 2 min of in-
cubation in serum (figure 3D), and there was an enhancement
of deposition in the presence of MBL, reaching significance at
16 min ( , paired Student’s t test of MFI; ).P ! .05 np 6
Opsonophagocytosis of C. albicans by DCs. PKH67-labeled
C. albicans yeasts were incubated with 20% MBL-deficient serum
supplemented with MBL (0, 1, or 5 mg/mL), for 16 min, the
time point at which maximal deposition of opsonic iC3b oc-
curred (figure 3D), followed by incubation with a suspension of
DCs for 1 h at 37C. Opsonophagocytosis was measured by use
of flow cytometry (figure 4). Opsonization of the yeasts in MBL-
deficient serum supplemented with 0 or 1 mg/mL MBL did not
influence DC phagocytosis, compared with that for unopsonized
yeasts. However, when opsonized in MBL-deficient serum with
5 mg/mL MBL, the relative percentage of yeast-ingested DCs was
reduced to (vs. control, , , n64% 4% 93% 3% Pp .0018
p4; vs. MBL-deficient serum with 0 mg/mL MBL, ,94% 4%
, ; paired Student’s t test) (figure 4).P ! .001 np 4
Influence of MBL on growth of C. albicans. Freshly grown
C. albicans yeasts were incubated with or without 5 mg/mL MBL
and then were incubated with MBL-deficient serum or heat-
inactivated MBL-deficient serum. As shown in figure 5, the
pretreatment of yeasts with MBL, followed by incubation with
either MBL-deficient serum or heat-inactivated MBL-deficient
serum separately, resulted in profound inhibition of growth,
compared with that observed when no MBL was used in the
pretreatment ( , for both unheated and heat-inacti-P ! .0001
vated serum, paired Student’s t test of curve areas; ).np 6
DISCUSSION
The innate immune system is an evolutionarily ancient form
of immunity and offers the main resistance to microbial path-
ogens during the early phase of infection [43]. At present, MBL
has been defined as an effector molecule, such as complement,
in mediating humoral innate immunity. The third pathway of
complement activation initiated by the MBL-MASP complex,
known as the lectin pathway, has been described to be high-
ly conserved in evolution as far back as ascidians, our closest
invertebrate relatives, suggesting that the lectin-based pathway
played a pivotal role in innate immunity before the evolution
of an adaptive immune system in jawed vertebrates [44]. Al-
though cell-mediated innate immunity is thought to be a pre-
dominant mechanism for the first-line host defense against C.
albicans [45–47], as a mediator in the highly conserved lectin-
based pathway, MBL can strongly bind to C. albicans [37]. In
the present study, we have sought to determine the role that
MBL plays in the innate defense against C. albicans. The data
presented here demonstrate that (1) MBL recognizes C. albicans
via its carbohydrate-recognition domain and induces aggluti-
nation of the organisms upon their outgrowth of hyphae, (2)
MBL mediates complement activation via the lectin pathway
and subsequent deposition of opsonic C3 fragment on C. al-
bicans, (3) MBL lacks function as an opsonin for phagocytosis
of C. albicans by DCs, and (4) MBL inhibits the growth of C.
albicans. These data suggest that MBL plays an important role
in the first-line defense against C. albicans without the need
for opsonophagocytosis by DCs.
We have demonstrated that MBL binds to C. albicans in a
Ca2+-dependent manner and that binding is inhibited by com-
peting sugars, such as mannan, implying involvement of the
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Figure 2. Agglutination induced upon the outgrowth of hyphae of Candida albicans, in the presence of mannose-binding lectin (MBL). C. albicans
were incubated with MBL (0 mg/mL: B, left panel, C, and E; 5 mg/mL: B, right panel, D, and F) in Ca2+-containing Hanks’ balanced salt solution with
10% heat-inactivated fetal calf serum for 20 min (A and B), 1 h (C and D), and 3 h (E and F), at 37C. Side scatter (SS) and forward scatter (FS)
plots of unicellular C. albicans (B), by flow cytometry, showed no agglutination induced in the presence of MBL. Agglutination was induced upon the
formation of hyphae of C. albicans in the presence of MBL (D and F). Bar, 20 mm, under phase-contrast light microscopy. Original magnifications: A,
C, and D, 320; E and F, 100.
carbohydrate-recognition domain of MBL. Also, MBL does not
affect the formation of hyphae of C. albicans but does induce
agglutination upon their outgrowth of hyphae, which suggests
a novel mechanism of MBL in innate immunity against C.
albicans. Steric hindrance by MBL may effectively inhibit the
spread of such a virulent form of C. albicans by blocking access
to appropriate receptors.
C. albicans activates both the alternative and the classical
pathway of complement [48], and the complement system is
important in the resistance against disseminated and cutaneous
candidiasis [49]. Antibodies protective against candidiasis re-
quire efficient deposition of complement on the fungal surface
[50]. In the present study, we have evaluated whether MBL
mediates the lectin pathway by initiating the binding of C4 and
C3 complement components to C. albicans. The MBL system
we used to study complement function involved serum samples
from MBL-deficient but generally healthy blood donors, to
which exogenous MBL was added, as adapted from previous
reports [4, 7]. Thus, each individual, whatever their background
levels of complements fixing antibodies to the yeasts, acted as
their own control. The addition of MBL to MBL-deficient se-
rum markedly enhanced the binding of C4, reaching its max-
imal level at 8 min, and also enhanced the subsequent binding
of iC3b to C. albicans, with its maximal level reached at 16
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Figure 3. Time course of deposition of mannose-binding lectin (MBL), C4, and iC3b on Candida albicans in MBL-deficient serum supplemented
with exogenous MBL. C. albicans were incubated with 20% MBL-deficient serum (from 6 individuals) with or without 5 mg/mL MBL, at 37C over
the course of 32 min. The deposition was determined by use of flow cytometry, as shown in representative profiles (A). B–D, Data are the
of 6 separate experiments. * , paired Student’s t test of mean fluorescence intensity (MFI).mean SEM P ! .05
min, suggesting that MBL mediates a sequential process in
complement activation via the lectin pathway independently of
the individual antibodies against the yeasts.
It has become clear that various C3 fragments (e.g., C3b,
iC3b, and C3d) provide alternative mechanisms for taking up
microorganisms via various complement receptors on phago-
cytic cells [51, 52]. An early study already showed that serum
with defective opsonization for phagocytosis by neutrophils has
lower deposition of C3b/iC3b on C. albicans [53], and the
presence of this opsonic defect is subsequently linked with low
levels of MBL [54]. One would presume that the MBL-mediated
enhancement of deposition of opsonic complement on C. al-
bicans, such as that of iC3b, promotes the uptake of the fungal
pathogen by phagocytic cells other than neutrophils, such as
DCs. Recent studies have demonstrated an important role of
DCs in mediating cellular immune response to C. albicans [34–
36]. In the present study, using the same MBL system as that
used for the complement activation, we found that MBL did
not enhance opsonophagocytosis of the yeasts by human DCs.
Furthermore, opsonization by other serum factors, such as the
background complements or antibodies in the serum samples
from MBL-deficient individuals, appeared not to enhance phago-
cytosis of C. albicans by DCs. Newman and Holly [34] observed
a similar phenomenon in their recent study in which opso-
nization of C. albicans in pooled human serum did not enhance
DC phagocytosis. Our data suggest that MBL, MBL-mediated
deposition of complement, and other serum factors lack op-
sonic function for phagocytosis of C. albicans by DCs. In a
recent study, Turner et al. [7] demonstrated that MBL and
MBL-mediated increases in opsonic C3 fragments enhance op-
sonophagocytosis of Staphylococcus aureus by neutrophils. The
role of MBL as an opsonin may thus critically depend on the
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Figure 4. Opsonophagocytosis of Candida albicans by human mono-
cyte-derived dendritic cells (DCs). C. albicans yeasts were labeled with
PKH67 (A, upper panel) and preincubated in the absence (control) or
presence of 20% mannose-binding lectin (MBL)–deficient serum supple-
mented with MBL (0, 1, or 5 mg/mL), for 16 min. Opsonized PKH67-labeled
yeasts were added to a suspension of unlabeled DCs (A, lower panel)
at the ratio of 5 organisms:1 DC, and the mixtures were incubated for
1 h at 37C. Phagocytosis was then analyzed by use of flow cytometry
and expressed as percentages of C. albicans–ingested DCs, as shown in
representative profiles (B), in which fluorescence due to nonengulfed or
adherent yeasts on DCs was quenched by adding trypan blue for 10 min
before analysis. The maximum percentages obtained within an experi-
ment were assigned a value of 100%, with all other percentages within
the same experiment expressed as a relative percentage of this maximum
(C). C, Data are the of 4 separate experiments. *mean SEM Pp
, vs. control (without opsonization), or , vs. MBL-deficient.0018 P ! .001
serum with 0 mg/mL MBL, paired Student’s t test. FITC, fluorescein
isothiocyanate; FS, forward scatter; SS, side scatter.
microbial species involved and the types of phagocytes to be
interacted with. DCs are capable of phagocytosing C. albicans
in the absence of opsonins, presumably via carbohydrate-rec-
ognition receptors (also known as C-type receptors), such as
mannose receptor [34, 35].
MBL, at a concentration of 5 mg/mL, was found to decrease
phagocytosis of C. albicans by DCs, which can possibly be at-
tributed to the large size of the agglutinated C. albicans complex-
es induced by MBL upon the outgrowth of hyphae during the
incubation period of the phagocytosis assay. The decrease can
also be the result of MBL interfering with the recognition of C.
albicans by the DC C-type receptors, which mediate subsequent
phagocytosis. Similar interference with the uptake of C. albicans
was observed on macrophages in an early study using rabbit
MBL [55]. Further clarification of whether MBL participates in
the regulation of cell-mediated immune response is required if
we are to fully understand the exact mechanisms that involve
MBL in the modulation of the DC-microbe interaction.
We next considered whether the increased rate of comple-
ment activation due to MBL could result in an inhibitory ef-
fect on the growth of C. albicans. MBL profoundly inhibited
the growth of C. albicans when added to MBL-deficient serum
during an incubation period of up to 6 h. Interestingly, we also
observed a significant inhibition of growth of C. albicans in the
presence of MBL when the serum was heat inactivated, a sit-
uation in which complement activation would not occur. This
suggests that MBL may have an intrinsic effect in inhibiting
fungal growth, but the maximal inhibition we observed with
unheated but MBL-supplemented serum indeed demonstrated
that complement activation via the lectin pathway is of im-
portance in inhibiting the growth of C. albicans. A recent study
has shown that the growth of C. dubliniensis, a Candida species
with phenotypical similarity to C. albicans, is decreased in the
presence of normal serum but not in the presence of C6/C7-
depleted serum [56], indicating a possible involvement of com-
plement activation up to the terminal complement system (i.e.,
the generation of the membrane attack complex) in inhibiting
the growth of Candida species. It is also possible that the avail-
ability of substrate to the organism becomes limited when C.
albicans are agglutinated with MBL upon their outgrowth of
hyphae during the time of growing. Such inhibition of growth
of C. albicans has also been observed with another member of
the collectin family, surfactant protein–D [57].
Lee et al. [58] recently demonstrated that, in mice deficient
in MBL-A, resistance to disseminated candidiasis is not altered,
suggesting the possibility that MBL deficiency can be compen-
sated by functional redundancy. Two hypotheses have been
proposed for the role of MBL. One of these envisages a major
role of the protein during the “window of vulnerability” dur-
ing early life [54]. The alternative hypothesis is that MBL is
important on primary contact with an organism, by providing
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Figure 5. Influence of mannose-binding lectin (MBL) on growth of
Candida albicans. C. albicans yeasts were incubated with or without 5
mg/mL purified MBL for 15 min at 37C. After washing, yeast cells were
resuspended in RPMI with 1.25% MBL-deficient serum. After 3 h and 6
h of incubation at 37C, the growth of C. albicans was determined by
use of the XTT-based cell proliferation assay (see Materials and Methods).
Solid lines, experiments using MBL-deficient serum; dashed lines, ex-
periments using the same serum, heat inactivated at 56C; and gray line,
control experiments in which yeasts were incubated without MBL and
serum. Data are plotted as ( ) of 3 separate exper-mean SEM np 6
iments. A490, absorbance at 490 nm.
humoral defense before antibody appears—so-called “ante-an-
tibody” [59]. In the present study, we used the MBL system
with exogenous MBL added to MBL-deficient serum, which
controls for the biological activities due to the background levels
of serum factors, such as complements and antibodies. Our
observations suggest a predominant role of MBL, among other
serum factors, at the early phase of defense against C. albicans.
Although MBL deficiency is one of the most common human
immunodeficiency states [22], invasive fungal infection is only
seen frequently in certain individuals, such as premature infants,
surgical patients, and patients with AIDS [23–29]; hence, MBL
may be critical only in certain clinical situations. Previous studies
have indicated the possible role of MBL in individuals with im-
munocompromised conditions who are susceptible to Candida
infection [60–65]. Further research targeted at the relative im-
portance of various mechanisms in the host defense against the
fungal pathogen will help to identify the possible role of MBL
replacement or adjunctive therapy in the clinical situations that
render individuals susceptible to fungal infection.
In summary, the present study has documented a direct in-
teraction between C. albicans and MBL, which results in ac-
celerated complement activation via the lectin pathway, leading
to inhibition of growth. We conclude that MBL has a significant
influence on the host innate immunity against C. albicans with-
out the need for opsonophagocytosis by DCs.
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